Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis
With
Genentech, Inc.
Age
12–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with a history of severe allergic asthma who completed the treatment period of CIGE250011E3 protocol, without experiencing any significant drug-related adverse events
Male or female patients 12-75 years of age who have given written informed consent approved by the ethical committee
You may not be if
Patients who had not received study medication for greater than 84 days since visit 38 of study CIGE240011E3
Pregnant females or nursing mothers
Patients with know hypersensitivity to any ingredients of Omalizumab or related drugs